RNAScope analysis of human pluripotent stem cells derived nociceptors

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95021Q00055 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13'Simplified Acquisition Procedures; and FAR Part 12'Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition to Advanced Cell Diagnostics, Inc. for the services of RNAScope analysis of human pluripotent stem cells derived nociceptors. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1). The rationale for not providing full and open competition is based on the fact that the data generated from this analysis will be compared to prior data generated for this project. To ensure a direct comparison of data and the continuity of science, the same vendor who performed the prior requirement must perform the current requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2021-04, with effective date January 19, 2021. (iv) The associated NAICS code 325413 and the small business size standard 1250 employees. This requirement is not set-aside. DESCRIPTION (v) The National Center for Advancing Translational Sciences (NCATS), Stem Cell Translation Laboratory (SCTL) has a requirement for RNAScope analysis of human pluripotent stem cells derived nociceptors. The contractor shall perform RNAscope Multiplex Fluorescent ISH assay for thirty?six (36) mRNAs in one (1) human iPSC?derived neural cell sample and perform positive and negative control assays to assess RNA quality and to optimize assay conditions for the sample set, followed by performance of target assays on the samples that pass QC. (vi) See the attached Statement of Work for complete requirement details: (vii) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated period of performance to be 16 weeks from the receipt of order (ARO) including the receipt of the samples intended for sequencing. The Government anticipates, but it does not guarantee, the shipment of 1 (one) full set of samples within 30 days, already included in the Period of Performance. TERMS AND CONDITIONS, PROVISIONS, AND REPRESENTATIONS (viii) The provision at FAR 52.212-1, Instructions to Offerors-Commercial Items (Jun 2020) (TAILORED), apply to this acquisition and is attached. The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2020) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions--Commercial Items (Oct 2018). Addendum to this FAR clause applies to this acquisition and is attached. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) (ix) The Quoters to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its quote. Offerors must complete and return the FAR representation 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020) and 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020), attached. (x) The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. FAR 52.212-4 Addendum - Supplier License Agreements, attached. FAR 52.212-4(g), Invoice, is supplemented by: NIH Invoice and Payment Instructions (12/2020), attached NIH electronic invoice instructions, attached (xi) The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition and is attached in full text. (xii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. EVALUATION (xiii) The Government plans to award a fixed-price purchase order resulting from this solicitation. The resulting award will be made to Advanced Cell Diagnostics provided it is technically acceptable and at a fair and reasonable price. If multiple quotations are received, the Government will use comparative evaluations to evaluate quotations for technical capability, past performance, and price. An award will be made to the vendor whose quotation is most advantageous to the Government. SUBMISSION INSTRUCTIONS (xiv) Responses to this solicitation must include sufficient information to establish the interested parties bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria. All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency. The Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response, and the completed representation in FAR Provisions 52.204-24 and 52.204-26 (attached). All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by 11:00 a.m., Eastern Time, on February 5, 2021, and reference Solicitation Number 75N95021Q00055. Responses must be submitted by email to Renato Gomes, Contract Specialist, contact@example.gov, tel. +1 (555) 000-0000. (xv) The name and telephone number of the individual to contact for information regarding the solicitation: Renato Gomes Contract Specialist Phone: +1 (555) 000-0000 Email: contact@example.gov ATTACHMENTS (xvi) Attachments: Statement of Work (SOW) The provision at FAR 52.212-1, Instructions to Offerors-Commercial Items (Jun 2020) (TAILORED) The provision at FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020) The provision at FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-4 Addendum - Supplier License Agreements The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders'Commercial Items (Jan 2021) NIH Invoice and Payment Provisions (12/2020) NIH Electronic Invoice Submission Instructions (10/2020)